PT-141 (Bremelanotide) vs AICAR
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Anti-Aging & LongevityFat Loss & Metabolic
AICAR- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
- Half-Life
- 2–3 hours
- ~2–3 hours
- Admin Route
- SubQ
- SubQ, IV
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 25–50 mg
- Frequency
- As needed (not daily)
- 3–5 times per week
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- AMPK activation mimics aerobic exercise adaptations
- Increased fat oxidation and endurance
- Mitochondrial biogenesis (PGC-1alpha)
- Improved insulin sensitivity and glucose metabolism
- Anti-inflammatory effects
- Potential cardiac protection during ischemia
- Synergistic with actual exercise training
- Reduces hepatic glucose production
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Hypoglycemia risk
- Lactic acidosis at high doses (animal data)
- Injection site irritation
- Stacks With
- —
- —